Systematic review with meta‐analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation

• Published in: Alimentary pharmacology & therapeutics 2019-02, Vol.49 (4), p.354-363
• Main Authors: Lai, Cheuk Yin, Sung, Joanne, Cheng, Felix, Tang, Whitney, Wong, Sunny H., Chan, Paul K.S., Kamm, Michael A., Sung, Joseph J.Y., Kaplan, Gilaad, Chan, Francis K.L., Ng, Siew C.
• Format: Article
• Language: English
• Subjects: Adult; Body mass; Body Mass Index; Clinical outcomes; Clostridium Infections - therapy; Colitis, Ulcerative - therapy; Crohn Disease - etiology; Crohn's disease; Data processing; Donors; Fecal Microbiota Transplantation - methods; Female; Heterogeneity; Humans; Inflammatory bowel diseases; Inflammatory Bowel Diseases - therapy; Intestine; Male; Mass Screening; Medical treatment; Meta-analysis; Microbiota; Remission; Reviews; Systematic review; Tissue Donors - statistics & numerical data; Transplantation; Ulcerative colitis
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/apt.15116

Summary Background Faecal microbiota transplantation (FMT) is effective for Clostridium difficile infections (CDI) refractory to standard treatment and is being studied in other diseases. Aim To evaluate donor characteristics, procedures and clinical outcomes of FMT. Methods We systematically reviewed FMT studies published up to 29 August 2018 using MEDLINE (R) and EMBASE and identified clinical studies with FMT donor information. We reported data on donor characteristics, screening criteria, administration, clinical outcomes and adverse events. Results Among 5267 reports, 239 full‐text articles were screened and 168 articles were included. FMT was performed commonly for CDI (n = 108) and inflammatory bowel disease (IBD) (n = 31). We reported characteristics of 1513 donors [58% male; mean age, 34.3 years; mean body mass index, 21.6]. Donors in Asia were younger than the West (mean age 30.7 vs 32.9, P = 0.00075). Less than 50% of studies screened donors for transmittable pathogens. Final cure rate for CDI was 95.6% (95% confidence interval [CI], 93.9%‐97.1%) and final remission rates for ulcerative colitis (UC) and Crohn's disease (CD) were 39.6% (95% CI, 25.4%‐54.6%) and 47.5% (95% CI, 29.4%‐65.8%), respectively. Cure rates in CDI and final remission rates for CD and UC were comparable across all routes of FMT administration. Overall adverse event incidence was